文献速递甲状腺与浅表介入US

甲状腺周围利多卡因灌注(PLI)对高强度聚焦超声(HIFU)消融良性甲状腺结节术中疼痛的影响

Effect of perithyroidal lignocaine infusion (PLI) to pain experienced during high-intensity focused ultrasound (HIFU) ablation of benign thyroid nodules.
PubMed 文献 · Eur Radiol · 2019-03-27

回顾分析205例接受HIFU消融良性甲状腺结节的患者,104例在常规静脉哌替啶和地西泮基础上加用甲状腺周围利多卡因灌注(I组),101例仅用静脉哌替啶和地西泮(II组)。I组术中VAS疼痛评分显著低于II组(51.30 vs 63.79,p=0.002)。多因素分析显示高龄、较低BMI、较高地西泮剂量和PLI使用是疼痛较轻的独立决定因素。

要点

  • HIFU消融良性甲状腺结节时,加用甲状腺周围利多卡因灌注可降低术中VAS疼痛评分(51.30 vs 63.79)。
  • 高龄、较低BMI和较高地西泮剂量与HIFU术中疼痛较轻独立相关。
  • PLI使用与疼痛较轻独立相关(OR=2.096,95%CI=1.121-3.922,p=0.020)。

核心结论

  • 在常规静脉哌替啶和地西泮基础上,甲状腺周围利多卡因灌注可为HIFU消融良性甲状腺结节提供额外镇痛;高龄、较低BMI和较高地西泮剂量与疼痛较轻显著相关。

研究设计与样本

  • 回顾性分析205例接受HIFU消融良性甲状腺结节的患者,I组104例(50.7%)在静脉哌替啶和地西泮基础上加用PLI,II组101例(49.3%)仅用静脉哌替啶和地西泮。

诊断标准与关键数值

  • 术中整体疼痛体验采用视觉模拟量表(VAS,0-100,0为无痛,100为最痛)评估;I组VAS 51.30 vs II组63.79,p=0.002。多因素分析中,高龄(OR=1.036,95%CI=1.008-1.065,p=0.011)、较低BMI(OR=1.202,95%CI=1.083-1.334,p=0.001)、较高地西泮剂量(OR=1.066,95%CI=1.018-1.114,p=0.006)和PLI使用(OR=2.096,95%CI=1.121-3.922,p=0.020)为疼痛较轻的独立决定因素。

临床应用与阅片要点

  • 原文结论认为PLI可在患者已接受常规静脉哌替啶和地西泮时提供额外镇痛;高龄、较低BMI和较高地西泮剂量与疼痛较轻显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess whether perithyroidal lignocaine infusion (PLI) could provide additional analgesia in high-intensity focused ultrasound (HIFU) treatment of benign thyroid nodules for patients already receiving their usual intravenous doses of Pethidine and Diazemuls.

METHODS: Two hundred and five patients who underwent HIFU ablation for a benign thyroid nodule were analyzed. Among them, 104 (50.7%) patients received PLI in addition to their boluses of Pethidine and Diazemuls before treatment (group I), while the rest (n = 101, 49.3%) received intravenous Pethidine and Diazemuls only (group II). After treatment, patients were asked to rate their overall pain experience on a visual analogue scale (VAS) (0-100) (0, no pain; 100, worse possible pain) during treatment. Binary logistic regression was performed to evaluate significant determinants for treatment pain including demographics, doses of medications, and treatment parameters.

RESULTS: VAS was significantly lower in group I (51.30 vs. 63.79, p = 0.002). In the multivariate analysis, older age at treatment (OR = 1.036, 95%CI = 1.008-1.065, p = 0.011), lower BMI (OR = 1.202, 95%CI = 1.083-1.334, p = 0.001), higher Diazemuls dose (OR = 1.066, 95%CI = 1.018-1.114, p = 0.006), and use of PLI (OR = 2.096, 95%CI = 1.121-3.922, p = 0.020) were independent determinants of less treatment pain.

CONCLUSIONS: PLI can provide additional analgesia in patients already receiving their usual intravenous doses of Pethidine and Diazemuls during HIFU ablation of benign thyroid nodules. Older age, lower body mass index, and greater Diazemuls (i.e., a sedative) dose are significantly associated with less treatment pain.

KEY POINTS: • PLI provided an additional analgesic effect in HIFU ablation of thyroid nodules. • Older age and lower BMI were significantly associated with less pain. • Higher doses of Diazemuls lessened pain during HIFU ablation.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lang BHH, Woo YC, Chiu KW, et al. Effect of perithyroidal lignocaine infusion (PLI) to pain experienced during high-intensity focused ultrasound (HIFU) ablation of benign thyroid nodules. Eur Radiol. 2019. PMID: 30919068. doi:10.1007/s00330-019-06160-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。